Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062023 · ClinicalTrials.gov registry record · Phase 2
Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00062023: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00062023 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062023, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether sulindac, aspirin, or ursodiol is more effective in preventing colorectal cancer. PURPOSE: This randomized phase II trial is studying how well sulindac works compared to aspirin or ursodiol in preventing colorectal cancer.
Interventions
- DRUG Sulindac
- DRUG Ursodiol
- DRUG Acetylsalicylic acid (Aspirin)
- OTHER Sulindac Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-06 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062023
The ClinicalTrials.gov registry entry for NCT00062023 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sulindac is the first listed.
NCT00062023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062023 about?
NCT00062023 is a clinical study titled "Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether sulindac, aspirin, or ursodiol is more effective in preventing colorectal cancer. PURPOSE: This randomized phase II trial is studying how well sulind...
What is the current status of trial NCT00062023?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2003-06. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00062023?
The interventions under investigation include: Sulindac (DRUG), Ursodiol (DRUG), Acetylsalicylic acid (Aspirin) (DRUG), Sulindac Placebo (OTHER).
Who is sponsoring clinical trial NCT00062023?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.